Expert Review of Vaccines

Scope & Guideline

Transforming Vaccine Development with Cutting-Edge Research.

Introduction

Immerse yourself in the scholarly insights of Expert Review of Vaccines with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1476-0584
PublisherTAYLOR & FRANCIS LTD
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Convergefrom 2002 to 2024
AbbreviationEXPERT REV VACCINES / Expert Rev. Vaccines
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The 'Expert Review of Vaccines' focuses on the comprehensive analysis, development, and evaluation of vaccines across various diseases, emphasizing real-world applications and economic implications. The journal aims to provide a platform for the latest advancements in vaccine research, safety, efficacy, and public health impact, catering to researchers, healthcare professionals, and policymakers.
  1. Vaccine Development and Innovation:
    The journal emphasizes the latest methodologies in vaccine development, including novel platforms such as mRNA, DNA, and protein-based vaccines, which are critical for addressing emerging infectious diseases.
  2. Immunogenicity and Safety Assessments:
    A core focus is on evaluating the immunogenicity, safety, and efficacy of vaccines through systematic reviews and meta-analyses, providing evidence-based insights into their performance in diverse populations.
  3. Public Health Impact and Economic Evaluations:
    The journal regularly publishes analyses of the public health impact of vaccination programs and conducts economic evaluations, helping to inform policy decisions and resource allocation.
  4. Emerging Infectious Diseases:
    There is a significant emphasis on vaccines targeting emerging infectious diseases, particularly in the context of global health crises like the COVID-19 pandemic.
  5. Vaccine Hesitancy and Acceptance:
    The journal explores factors influencing vaccine hesitancy and public acceptance, providing insights into strategies to enhance vaccination rates.
  6. Global Health Perspectives:
    The scope includes discussions around global vaccination strategies and challenges, particularly in low- and middle-income countries, highlighting disparities in vaccine access.
The 'Expert Review of Vaccines' has identified several emerging themes and trends in recent publications that reflect the dynamic landscape of vaccine research and public health priorities. These trends indicate a shift towards innovative solutions and a broader understanding of vaccination in the context of global health.
  1. COVID-19 Vaccine Research:
    A significant increase in publications related to COVID-19 vaccines, including booster strategies, efficacy against variants, and real-world effectiveness, reflecting the urgent need for ongoing research in response to the pandemic.
  2. Personalized and Targeted Vaccines:
    Emerging interest in personalized vaccine approaches, particularly in cancer immunotherapy, as researchers explore tailored solutions based on individual immunological profiles.
  3. Innovations in Vaccine Delivery Systems:
    Advancements in vaccine delivery technologies, such as microneedles and nasal vaccines, are gaining attention, indicating a trend towards improving the accessibility and efficacy of vaccinations.
  4. Addressing Vaccine Hesitancy:
    Increased focus on understanding and addressing vaccine hesitancy, particularly in specific demographics, as public health initiatives aim to enhance vaccination uptake globally.
  5. Economic Impact of Vaccination Programs:
    Growing emphasis on the economic evaluations of vaccination strategies, assessing cost-effectiveness and budget implications for public health policies.
  6. Global Vaccine Equity and Access:
    Heightened discussions around vaccine equity, particularly in the context of low- and middle-income countries, as the global community seeks to address disparities in vaccine distribution and access.

Declining or Waning

While the 'Expert Review of Vaccines' continues to cover a broad range of topics, certain themes appear to be declining in frequency or prominence in recent publications. This may reflect shifts in research focus or changes in public health priorities.
  1. Traditional Vaccination Strategies:
    There seems to be a decline in publications focusing solely on traditional vaccination strategies, as the field moves towards more innovative approaches and technologies.
  2. Herd Immunity Discussions:
    Discussions centered on herd immunity in isolation have decreased, likely due to the evolving understanding of vaccine efficacy and the complexities introduced by variants of diseases such as COVID-19.
  3. Vaccine Adverse Event Reporting:
    While safety remains a priority, specific studies solely focusing on adverse event reporting have diminished, as the field shifts towards comprehensive safety profiles and real-world effectiveness.
  4. Longitudinal Studies on Vaccine Efficacy:
    There is a noticeable decrease in longitudinal studies focused exclusively on vaccine efficacy over time, as recent research emphasizes immediate effectiveness and safety outcomes.
  5. Single-Disease Focus:
    The journal is moving away from publications that focus on single diseases. Instead, there is a growing trend towards multi-pathogen and integrated approaches to vaccination.

Similar Journals

Clinical and Experimental Vaccine Research

Empowering research to combat infectious diseases.
Publisher: KOREAN VACCINE SOCISSN: 2287-3651Frequency: 2 issues/year

Clinical and Experimental Vaccine Research, an esteemed journal published by the Korean Vaccine Society, serves as a vital platform for disseminating groundbreaking research in the fields of Immunology, Infectious Diseases, and Public Health. Since its inception in 2012, this open-access journal has been committed to advancing knowledge and fostering collaboration among professionals dedicated to vaccine development and evaluation. With an impactful presence and a Q3 ranking in several categories on the Scopus index, it reflects a robust commitment to quality, evidenced by its placement within the 41st to 59th percentiles across multiple disciplines related to medicine and health. Situated in Seoul, South Korea, at the Department of Pediatrics, Yonsei University Severance Children's Hospital, the journal not only provides a crucial resource for researchers and practitioners but also enhances the global discourse on vaccination strategies and public health interventions. By contributing to the ongoing dialogue in vaccine research, this journal plays an essential role in shaping future health policies and practices.

Infectious Diseases

Pioneering Insights in Microbiology and Immunology
Publisher: TAYLOR & FRANCIS LTDISSN: 2374-4235Frequency: 12 issues/year

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

Open Forum Infectious Diseases

Empowering global health through accessible science.
Publisher: OXFORD UNIV PRESS INCISSN: 2328-8957Frequency: 12 issues/year

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

Eurosurveillance

Innovating public health solutions through shared knowledge.
Publisher: EUR CENTRE DIS PREVENTION & CONTROLISSN: 1025-496XFrequency: 50 issues/year

Eurosurveillance is a prestigious journal dedicated to the field of epidemiology, public health, and infectious diseases, published by the European Centre for Disease Prevention and Control since 1996. With an impressive Q1 ranking across various categories, including Epidemiology and Public Health, it consistently stands at the forefront of research dissemination, making it an invaluable resource for researchers, professionals, and students alike. The journal boasts an outstanding reputation, as evidenced by its Scopus rankings, where it ranks in the top 1% to 3% in multiple relevant categories. As an Open Access publication, Eurosurveillance ensures that vital findings are freely accessible to a global audience, fostering collaboration and innovation in the fight against infectious diseases. With a dedicated reach from 2001 to 2024, the journal addresses contemporary challenges in public health and virology, reinforcing its significance in shaping policies and research initiatives across the world.

Journal of the Pediatric Infectious Diseases Society

Advancing pediatric health through innovative research.
Publisher: OXFORD UNIV PRESSISSN: 2048-7193Frequency: 4 issues/year

Journal of the Pediatric Infectious Diseases Society, published by Oxford University Press, stands as a pivotal platform for advancing knowledge in the realm of pediatric infectious diseases. With an ISSN of 2048-7193 and an E-ISSN of 2048-7207, this esteemed journal has garnered significant recognition in the academic community, achieving influential rankings such as Q1 in Pediatrics, Perinatology and Child Health and Q2 in Infectious Diseases. With converged years from 2012 to 2024, it aims to publish cutting-edge research, reviews, and clinical practices that address the challenges and innovations in the field. The journal's strong performance, reflected in its Scopus ranks (33rd percentile in Pediatrics and 97th in Infectious Diseases), underscores its impact on the global healthcare landscape. As a non-open access journal, it provides exclusive content essential for researchers, medical professionals, and students dedicated to enhancing pediatric healthcare outcomes.

Virulence

Empowering Researchers with Open Access Discoveries
Publisher: TAYLOR & FRANCIS INCISSN: 2150-5594Frequency: 8 issues/year

Virulence, a leading academic journal published by Taylor & Francis Inc, is dedicated to advancing the understanding of virulence mechanisms in pathogens across various infectious diseases. Since becoming an Open Access publication in 2018, it has broadened the accessibility of cutting-edge research for a global audience, promoting collaboration and knowledge-sharing among researchers, professionals, and students alike. With a significant impact within its field, the journal boasts impressive 2023 quartile rankings: Q2 in Immunology and Q1 in both Infectious Diseases and Microbiology, alongside notable standings in Parasitology. The current Scopus rankings reinforce its prominence, with high percentiles indicating its influence and relevance in advancing scientific inquiry. Covering a period from 2010 to 2024, Virulence serves as an essential platform for innovative research that not only addresses the critical challenges in understanding pathogen behavior but also contributes towards global health solutions, establishing it as a vital resource in the rapidly evolving fields of immunology, microbiology, and parasitology.

Med

Advancing Medical Knowledge, Together.
Publisher: CELL PRESSISSN: 2666-6340Frequency: 12 issues/year

Med, an esteemed journal published by CELL PRESS, stands at the forefront of interdisciplinary medical research, making significant contributions to the field of Medicine since its inception in 2020. With an impressive Q1 ranking in the Medicine (miscellaneous) category and a notable 96th percentile ranking in General Medicine according to Scopus, this journal is dedicated to disseminating high-quality research that advances medical knowledge and practice. Med provides a platform where researchers, professionals, and students can share their findings and insights, fostering a collaborative environment that bridges various aspects of medicine. While offering a comprehensive body of research, Med is committed to promoting open communication within the scientific community, ensuring that valuable information is accessible to those who seek to enhance their understanding and application of medical science. With a strong presence in the United States and a global readership, Med is poised to influence the future of healthcare significantly.

JOURNAL OF CLINICAL VIROLOGY

Transforming Knowledge into Solutions for Viral Challenges
Publisher: ELSEVIERISSN: 1386-6532Frequency: 12 issues/year

Journal of Clinical Virology, published by Elsevier, stands at the forefront of virology research, focusing on the clinical implications of viral diseases. With an impressive impact factor representative of its Q1 categorization in both Infectious Diseases and Virology, this journal is essential for researchers and healthcare professionals aiming to keep pace with evolving knowledge and treatments in virology. Since its inception in 1998, it has provided a vital platform for the dissemination of significant breakthroughs, now continuing through to 2024. The journal boasts competitive Scopus ranks, placing it in the 95th percentile for Infectious Diseases and the 91st percentile for Virology. Scholars can benefit from its selective Open Access options, promoting widespread access to cutting-edge research. With an ever-increasing demand for innovative solutions to viral infections, Journal of Clinical Virology remains dedicated to fostering advancements in the field, making it a key resource for anyone invested in virology and infectious disease management.

Vaccines

Advancing vaccine knowledge for a healthier tomorrow.
Publisher: MDPIISSN: Frequency: 12 issues/year

Vaccines, published by MDPI in Switzerland, is a leading open access journal that has been at the forefront of vaccine research since its inception in 2013. With an impressive impact factor and consistently ranked in the Q1 and Q2 quartiles across leading categories such as Drug Discovery, Immunology, Infectious Diseases, and Pharmacology, it provides a vital platform for researchers to share their findings and advance the field. The journal is dedicated to delivering high-quality original research articles, reviews, and case studies that address the challenges and innovations in vaccine development and immunization strategies worldwide. Open access since its launch, Vaccines ensures that cutting-edge research is widely available to the global academic community and public health professionals, thereby fostering collaboration and enhancing knowledge in this critical area of public health.

Vaccine: X

Fostering knowledge and innovation in vaccine research.
Publisher: ELSEVIERISSN: 2590-1362Frequency:

Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.